|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.770 USD | -0.57% |
|
-6.80% | +19.16% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"
| Capitalization | 161M 139M 125M 120M 219M 14.78B 229M 1.48B 593M 7.09B 604M 591M 25.36B | P/E ratio 2026 * |
-1.73x | P/E ratio 2027 * | -3x |
|---|---|---|---|---|---|
| Enterprise value | 443M 382M 345M 331M 603M 40.7B 631M 4.07B 1.63B 19.52B 1.66B 1.63B 69.8B | EV / Sales 2026 * |
3.18x | EV / Sales 2027 * | 0.79x |
| Free-Float |
93.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Karyopharm Therapeutics Inc.
| 1 day | -0.57% | ||
| 1 week | -6.80% | ||
| Current month | -6.80% | ||
| 1 month | +40.10% | ||
| 3 months | +48.90% | ||
| 6 months | +40.32% | ||
| Current year | +19.16% |
| 1 week | 8.57 |  | 9.59 |
| 1 month | 6.2 | | 10.99 |
| Current year | 5.88 | | 10.99 |
| 1 year | 3.51 | | 10.99 |
| 3 years | 3.51 | | 73.05 |
| 5 years | 3.51 | | 220.95 |
| 10 years | 3.51 | | 444.15 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 58 | 02/05/2021 |
Lori Macomber
DFI | Director of Finance/CFO | 55 | 02/01/2025 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 31/03/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Barry Greene
BRD | Director/Board Member | 62 | 31/12/2012 |
| Director/Board Member | 61 | 31/03/2013 | |
Garen Bohlin
BRD | Director/Board Member | 78 | 02/10/2013 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.57% | -6.80% | +27.29% | -81.20% | 161M | |
| -0.66% | -2.79% | +7.40% | +1.97% | 77.98B | |
| -2.68% | -0.52% | +33.16% | +213.44% | 55.42B | |
| -0.18% | +64.40% | +64.40% | +64.40% | 51.24B | |
| -3.00% | -3.68% | -44.45% | -51.16% | 49.37B | |
| -1.71% | -3.62% | +22.94% | -29.71% | 27.13B | |
| -2.43% | -1.96% | +47.49% | -63.03% | 20.74B | |
| -1.43% | -5.26% | +35.53% | +30.02% | 19.09B | |
| -4.20% | -3.33% | +104.74% | +100.13% | 18.48B | |
| -1.21% | -4.75% | +27.92% | +58.10% | 14.15B | |
| Average | -1.80% | -3.57% | +32.64% | +24.29% | 33.38B | |
| Weighted average by Cap. | -1.72% | -2.98% | +24.39% | +41.57% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 139M 120M 108M 104M 189M 12.78B 198M 1.28B 513M 6.13B 522M 511M 21.92B | 204M 176M 159M 152M 278M 18.74B 291M 1.88B 752M 8.99B 765M 749M 32.15B |
| Net income | -128M -111M -99.76M -95.72M -175M -11.78B -183M -1.18B -472M -5.65B -481M -471M -20.2B | -137M -118M -107M -102M -186M -12.58B -195M -1.26B -505M -6.03B -514M -503M -21.58B |
| Net Debt | 282M 243M 219M 211M 384M 25.92B 402M 2.59B 1.04B 12.43B 1.06B 1.04B 44.45B | - |
Employees
228
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/03/26 | 8.770 $ | -0.57% | 725,196 |
| 05/03/26 | 8.820 $ | -3.61% | 509,407 |
| 04/03/26 | 9.150 $ | +0.22% | 397,719 |
| 03/03/26 | 9.130 $ | -4.80% | 1,718,600 |
| 02/03/26 | 9.590 $ | +1.91% | 507,469 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.770USD
Average target price
15.33USD
Spread / Average Target
+74.84%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- KPTI Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition